Company Peloton Therapeutics, Inc.

Peloton Therapeutics, Inc. is a clinical stage pharmaceutical company. The Company is focused on developing medicines for patients with cancer and other conditions. The Company's product pipeline includes Hypoxia-inducible factor-2? (HIF-2?). HIF-2? is a transcription factor that, in part, regulates the body's response to diminished availability of oxygen. The Company's lead drug candidate, PT2977, is an oral HIF-2?. The Company is focused on developing PT2977 for the treatment of kidney cancer, specifically metastatic clear cell renal cell carcinoma (mRCC) and von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC). HIF-2? is aberrantly activated in these diseases as a result of the inactivity of the VHL tumor suppressor. The Company is also developing PT2567, an oral HIF-2? inhibitor, for non-oncology indications.

Number of employees: 64